AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7483798
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - three doses of 20 micrograms i.m. (n = 103)
Trial: 7483798
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B - first dose i.d. (2 micrograms), second and third doses i.m. (20 micrograms) (n = 97)
Trial: 7483798
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C - first and second doses i.d. (2 micrograms), third dose i.m. (20 micrograms) (n = 100)
Trial: 29903093
Drug: BP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP 200 μmol/L
Trial: 29903093
Drug: BP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP 400 μmol/L
Trial: 29903093
Drug: BP 800
RxNorm normalized name: Peptimax 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP 800 μmol/L
Trial: 25552576
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (40 to 60 minutes, 3 times weekly for 6 months)
Trial: 22057944
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (40 mg, 1 ml)
Trial: 22057944
Drug: Betametazone disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betametazone disodium phosphate (3 mg, 1 ml)
Trial: 22057944
Drug: Triamsinolon acetonate
RxNorm normalized name: Acetone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamsinolon acetonate (40 mg, 1 ml)
Trial: 22057944
Drug: Serum physiological
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum physiological (0.09% NaCl, 1 ml)
Trial: 19421791
Drug: Aceclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac (100 mg) - Tizanidine (2 mg) b.i.d for 7 days
Trial: 19421791
Drug: Aceclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac (100 mg) alone b.i.d for 7 days
Trial: 7616869
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg/day continuously
Trial: 7616869
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg/day combined with medroxyprogesterone acetate 5 mg/day sequentially
Trial: 7001490
Drug: pyritinol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyritinol (800 mg daily)
Trial: 31141728
Drug: Sequential DL‐PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential DL‐PDT plus IM
Trial: 17542150
Drug: Apricitabine (ATC)
RxNorm normalized name: Emtricitabine
DrugBank: Apricitabine (DB12855)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apricitabine (ATC) 1,200 mg/day
Trial: 17542150
Drug: Apricitabine (ATC)
RxNorm normalized name: Emtricitabine
DrugBank: Apricitabine (DB12855)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apricitabine (ATC) 1,600 mg/day
Trial: 15581204
Drug: Mycobacterium vaccae
RxNorm normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium vaccae (SRL172) immunotherapy
Trial: 8636652
Drug: L-glutamine, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine, 4 gm swish and swallow twice a day, from day 1 of chemotherapy for 28 days or for 4 days past the resolution of any post-chemotherapy mucositis
Trial: 25424601
Drug: Vitamin D3-fortified
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3-fortified doogh (FD; containing 500 IU/250 ml)
Trial: 25424601
Drug: Plain doogh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain doogh (PD; containing 150 mg calcium and no vitamin D/250 ml)
Trial: 21140164
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) 1 mg/day for 7 days
Trial: 16137053
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (TV = 7 ml/kg, f=12 bpm)
Trial: 16137053
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (TV=5 ml/kg, f=15 bpm)
Trial: 16137053
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (TV=7 ml/kg, f=15 bpm)
Trial: 10895409
Drug: Adenosine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (20 mg/10 min)
Trial: 8222787
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 50, 100, 200, and 400 micrograms twice daily
Trial: 3513105
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (Salbutamol)
Trial: 31752498
Drug: Dosing practices
RxNorm normalized name: Practical Alchemy Purify and Protect Duo KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing practices based on current recommendations (46%-76% adherence)
Trial: 31752498
Drug: Lean body
RxNorm normalized name: Cleanser Topical application Soap [NIVEA MEN ACTIVE CLEAN BODY WASH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean body weight for dosing propofol, non-depolarising muscle relaxants, sugammadex, and opioids
Trial: 31752498
Drug: Total body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total body weight for dosing suxamethonium
Trial: 31752498
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of resources to assist dosing practices in obesity
Trial: 31752498
Drug: Increased incidences
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased incidences of adverse events related to drug dosing
Trial: 29659887
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in HOMA-IR on study treatment
Trial: 27598803
Drug: High-dose external
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose external beam radiation therapy (EBRT) up to 80 Gy plus androgen deprivation therapy (ADT) for 2 to 3 years
Trial: 15798459
Drug: Complete clamping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete clamping (CC)
Trial: 14564429
Drug: Desmopressin nasal
RxNorm normalized name: desmopressin nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin nasal spray (test preparation)
Trial: 6641534
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (20 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Trial: 6641534
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (40 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Trial: 6641534
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (40 micrograms HBs antigen, 5 doses at 0, 1, 2, 4, 6 months)
Trial: 6641534
Drug: Passive-active vaccination
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive-active vaccination (40 micrograms HBs antigen at 0, 1, 2, 4, 6 months + 3 ml hepatitis B immunoglobulin at 0, 2 months)
Trial: 6641534
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (3 doses at 0, 1, 6 months)
Trial: 26465403
Drug: Injection with
RxNorm normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection with saline
Trial: 26465403
Drug: Injection with
RxNorm normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection with anesthetic
Trial: 23102084
Drug: Single-dose cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cefazolin (1 g) during surgery
Trial: 23102084
Drug: Multiple-dose antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose antimicrobial prophylaxis (5 doses every 12 hours postoperatively)
Trial: 19445860
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone (375 microg, once daily for 3 months)
Trial: 11354303
Drug: Prosorba column
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosorba column treatment
Trial: 9753292
Drug: CL 316,243
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CL 316,243 (1,500 mg/day)
Trial: 31344188
Drug: Watsu therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watsu therapy
Trial: 25590673
Drug: Chlorella vulgaris
RxNorm normalized name: CHLORELLA VULGARIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella vulgaris supplement for 2 weeks
Trial: 22001994
Drug: Pramipexole (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.7 mg free base, 3 times a day)
Trial: 22001994
Drug: Ropinirole (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (12 mg, once daily)
Trial: 22001994
Drug: Levodopa/Carbidopa (100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/Carbidopa (100/25 mg, 3 times a day)
Trial: 17023095
Drug: 9-valent conjugate
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent conjugate pneumococcal vaccine
Trial: 8844631
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral conjugated equine estrogen 0.625 mg daily
Trial: 8844631
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal estradiol-17 beta 50 mcg twice weekly
Trial: 23451547
Drug: Single take
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single take home dose of infant nevirapine
Trial: 16368848
Drug: Monitoring group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring group: tracheal intubation at maximum block based on monitoring after atracurium 0.5 mg/kg
Trial: 16368848
Drug: 2‐min group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐min group: tracheal intubation 2 min after injection of atracurium 0.5 mg/kg
Trial: 10376236
Drug: Clonazepam (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (1-4 mg/d, flexible dose)
Trial: 1794360
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg/day
Trial: 29744754
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser treatment for seven sessions at 2-week intervals
Trial: 29744754
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser treatment for three sessions at 6-week intervals
Trial: 25321188
Drug: buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 days
Trial: 25321188
Drug: buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 28 days
Trial: 20520636
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of abnormal FLC estimate and/or presence of high-risk IgH translocation
Trial: 11600561
Drug: Cromone treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromone treatment (control group)
Trial: 7991907
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural block with bupivacaine (8 ml of 0.5% bupivacaine with adrenalin 1:200.000) administered 30 min before surgery and combined anesthesia with isoflurane.
Trial: 7991907
Drug: Conventional balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional balanced anesthesia with isoflurane and endovenous fentanyl (2.5 micrograms/kg) and saline solution administered through an epidural catheter.
Trial: 2575367
Drug: Cicletanine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine (50 to 100 mg/day) combined with beta-blockers
Trial: 2575367
Drug: Cicletanine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine (50 to 100 mg/day) combined with calcium inhibitors
Trial: 2575367
Drug: Cicletanine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine (50 to 100 mg/day) combined with angiotensin-converting enzyme inhibitors
Trial: 2575367
Drug: Cicletanine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine (50 to 100 mg/day)
Trial: 182348
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments combined (Stage III and IV patients)
Trial: 30550135
Drug: Intratympanic injection
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic injection of dexamethasone 0.5 ml
Trial: 30550135
Drug: Postauricular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postauricular injection of methylprednisolone 40 mg
Trial: 26499352
Drug: Probiotics group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics group A (1 g Clostridium butyricum MIYAIRI twice daily)
Trial: 26499352
Drug: Probiotics group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics group B (Bifidobacterium longum BB536 twice daily)
Trial: 26499352
Drug: Digestive enzymes
RxNorm normalized name: DIGESTIVE ENZYMES TAB,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digestive enzymes group (Aczym, containing 100 mg takadiastase N, 20 mg cellulase AP, 50 mg lipase MY, and 100 mg pancreatin, twice daily)
Trial: 21878847
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide 2%-timolol 0.5% twice a day
Trial: 17343821
Drug: Pre-treatment SSRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment SSRI use
Trial: 17343821
Drug: Post-treatment SSRI
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment SSRI use
Trial: 17343821
Drug: Pre-treatment A/D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment A/D use
Trial: 17343821
Drug: Post-treatment A/D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment A/D use
Trial: 17343821
Drug: Pre-treatment BZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment BZ use
Trial: 9334143
Drug: Pefloxacin mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin mesylate, administered twice a day in a daily dose of 0.8 to 1.2 g
Trial: 3440039
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available reference preparation
Trial: 31524967
Drug: Microneedling followed
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling followed by topical application of 5-fluorouracil
Trial: 26786148
Drug: P1000/Ca0 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1000/Ca0 (1 g/d phosphorus)
Trial: 26786148
Drug: P1000/Ca500 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1000/Ca500 (1 g/d phosphorus and 0.5 g/d calcium)
Trial: 26786148
Drug: P1000/Ca1000 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1000/Ca1000 (1 g/d phosphorus and 1 g/d calcium)
Trial: 17373141
Drug: Antiviral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral and analgesic therapies
Trial: 17373141
Drug: Childhood vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Childhood vaccine against varicella zoster virus
Trial: 17373141
Drug: More potent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More potent vaccine against varicella for adults
Trial: 14649578
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant (FS) 10 mL total
Trial: 11001889
Drug: Prophylactic methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic methylprednisolone (0.5 mg/kg on days 14 to 20, 1 mg/kg on days 21 to 34, 0.5 mg/kg on days 35 to 48, tapered and discontinued on day 110)
Trial: 3307283
Drug: Analgetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgetic treatment without immobilization
Trial: 26156412
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (100 mg once a day for 12 weeks)
Trial: 21779958
Drug: Idebenone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months
Trial: 21779958
Drug: Idebenone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone at a weight-adjusted dose of 450/900 or 1,350/2,250 mg/day for 6 months (during the IONIA study)
Trial: 21779958
Drug: Idebenone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months (IONIA-E study)
Trial: 19176289
Drug: Interferon‐beta (IFNbeta)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐beta (IFNbeta) treatment
Trial: 12475391
Drug: BATT 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BATT 10 mg
Trial: 12475391
Drug: BATT 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BATT 20 mg
Trial: 12475391
Drug: BATT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BATT 30 mg
Trial: 3341564
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of EMLA cream for 15 minutes
Trial: 3341564
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of lidocaine
Trial: 3341564
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of EMLA cream for 80 minutes
Trial: 3341564
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of EMLA cream for 100 minutes
Trial: 3341564
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of EMLA cream for 120 minutes
Trial: 30212404
Drug: 100% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% daily dosing of TDF/FTC for 12 weeks
Trial: 30212404
Drug: 67% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 67% daily dosing of TDF/FTC for 12 weeks
Trial: 30212404
Drug: 33% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% daily dosing of TDF/FTC for 12 weeks
Trial: 28399933
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.2 mg/kg, maximum 5.0 mg)
Trial: 28399933
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.5 mg/kg, maximum 20 mg)
Trial: 28399933
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of midazolam (1.0 mg/kg, maximum 20 mg)
Trial: 23982225
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) focusing on behavioral exposure
Trial: 10934672
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg + Irbesartan 300 mg
Trial: 1477436
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine 140 micrograms/kg/min for six minutes
Trial: 1477436
Drug: Oral dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dipyridamole suspension 300 mg
Trial: 1477436
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine and oral dipyridamole